Large Intestine Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LRG016 MIFTS: 30	Large Intestine Adenocarcinoma Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases
Genes Tissues Related diseases Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Large Intestine Adenocarcinoma

MalaCards integrated aliases for Large Intestine Adenocarcinoma:

Name: Large Intestine Adenocarcinoma ¹² ¹⁵

Adenocarcinoma of Large Intestine ⁷³

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Gastrointestinal diseases Endocrine diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0050913

UMLS ⁷³ C1319315

Sources

Summaries for Large Intestine Adenocarcinoma

Disease Ontology : ¹² A large intestine cancer that has material basis in epithelial cells of glandular origin.

MalaCards based summary : Large Intestine Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to cystic basal cell carcinoma and seminal vesicle adenocarcinoma. An important gene associated with Large Intestine Adenocarcinoma is KRT20 (Keratin 20), and among its related pathways/superpathways are Endometrial cancer and Development EGFR signaling pathway. The drugs Iron and Ferric Compounds have been mentioned in the context of this disorder. Affiliated tissues include lung, kidney and colon, and related phenotypes are Reduced mammosphere formation and cellular

Sources

Related Diseases for Large Intestine Adenocarcinoma

Diseases in the Large Intestine Adenocarcinoma family:

Small Intestine Adenocarcinoma

Diseases related to Large Intestine Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 137)

#	Related Disease	Score	Top Affiliating Genes
1	cystic basal cell carcinoma	10.2	KRT20 KRT7
2	seminal vesicle adenocarcinoma	10.2	KRT20 KRT7
3	transverse colon cancer	10.2	KRT20 KRT7
4	appendix adenocarcinoma	10.2	KRT20 KRT7
5	malignant syringoma	10.2	KRT20 KRT7
6	glandular cystitis	10.2	KRT20 KRT7
7	papillary transitional carcinoma	10.2	KRT20 KRT7
8	eyelid carcinoma	10.2	KRT20 KRT7
9	krukenberg carcinoma	10.2	KRT20 KRT7
10	small cell carcinoma of the bladder	10.2	KRT20 KRT7
11	small cell carcinoma	10.2	KRT20 KRT7
12	intratubular embryonal carcinoma	10.2	KRT20 KRT7
13	bile duct cystadenocarcinoma	10.2	KRT20 KRT7
14	bile duct adenoma	10.2	KRT20 KRT7
15	jejunal adenocarcinoma	10.2	KRT20 KRT7
16	ovarian mucinous adenocarcinoma	10.2	KRT20 KRT7
17	mucinous adenocarcinoma	10.2	KRT20 KRT7
18	thymus adenocarcinoma	10.2	KRT20 KRT7
19	appendix disease	10.2	KRT20 KRT7
20	meibomian cyst	10.2	KRT20 KRT7
21	bladder lymphoma	10.2	KRT20 KRT7
22	papillary serous adenocarcinoma	10.2	KRT20 KRT7
23	chronic cystitis	10.2	KRT20 KRT7
24	medulloepithelioma	10.2	KRT20 KRT7
25	glycogen-rich clear cell breast carcinoma	10.2	KRT20 KRT7
26	rectum adenocarcinoma	10.2	KRT20 KRT7
27	renal pelvis carcinoma	10.2	KRT20 KRT7
28	mucinous bronchioloalveolar adenocarcinoma	10.2	KRT20 KRT7
29	ampulla of vater adenocarcinoma	10.2	KRT20 KRT7
30	biliary papillomatosis	10.2	KRT20 KRT7
31	endocervical adenocarcinoma	10.2	KRT20 KRT7
32	cervical adenocarcinoma	10.2	KRT20 KRT7
33	eccrine sweat gland neoplasm	10.2	KRT20 KRT7
34	dermoid cyst	10.2	KRT20 KRT7
35	large cell acanthoma	10.2	KRT7 MTOR
36	cystadenofibroma	10.2	KRT20 KRT7
37	ovarian mucinous neoplasm	10.2	KRT20 KRT7
38	thymus lipoma	10.2	KRT20 KRT7
39	mucinous cystadenocarcinoma	10.2	KRT20 KRT7
40	appendix cancer	10.2	KRT20 KRT7
41	prostatic acinar adenocarcinoma	10.2	KRT20 KRT7
42	immune system organ benign neoplasm	10.2	KRT20 KRT7
43	cystic teratoma	10.2	KRT20 KRT7
44	morpheaform basal cell carcinoma	10.2	CDH1 KRT20
45	ovarian cystic teratoma	10.2	KRT20 KRT7
46	pancreatic mucinous cystadenoma	10.2	KRT20 KRT7
47	cystadenoma	10.2	KRT20 KRT7
48	horseshoe kidney	10.2	KRT20 KRT7
49	clear cell adenofibroma	10.2	KRT7 MTOR
50	renal pelvis adenocarcinoma	10.2	CDH1 KRT7

Graphical network of the top 20 diseases related to Large Intestine Adenocarcinoma:

Sources

Symptoms & Phenotypes for Large Intestine Adenocarcinoma

GenomeRNAi Phenotypes related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.02	CDH1 EIF4EBP1 KRT7 MCM3 MTOR

MGI Mouse Phenotypes related to Large Intestine Adenocarcinoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	9.17	CDH1 CTNNB1 EIF4EBP1 KRT7 MCM3 MTOR

Sources

Drugs & Therapeutics for Large Intestine Adenocarcinoma

Drugs for Large Intestine Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Iron

Approved

Phase 4

7439-89-6

23925

Ferric Compounds

Phase 4

Hematinics

Phase 4,Phase 3,Phase 2,Phase 1

Hepcidins

Phase 4

Iron Supplement

Phase 4

Oxaliplatin

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

61825-94-3

43805 6857599 5310940 9887054

Bevacizumab

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

216974-75-3

Capecitabine

Approved, Investigational

Phase 3,Phase 2,Phase 1

154361-50-9

60953

Levoleucovorin

Approved, Investigational

Phase 3,Phase 2,Phase 1

68538-85-2

Fluorouracil

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

51-21-8

3385

leucovorin

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

58-05-9

6006 143

Irinotecan

Approved, Investigational

Phase 2, Phase 3,Phase 1

100286-90-6, 97682-44-5

60838

Atezolizumab

Approved, Investigational

Phase 3,Phase 2

1380723-44-3

Nicotine

Approved

Phase 3

54-11-5

942 89594

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2,Phase 1,Not Applicable

59-30-3

6037

Glutamic Acid

Approved, Nutraceutical

Phase 3

56-86-0

33032

Immunologic Factors

Phase 3,Phase 2,Phase 1,Not Applicable

Angiogenesis Inhibitors

Phase 3,Phase 2,Phase 1,Not Applicable

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1,Not Applicable

Angiogenesis Modulating Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Antimetabolites

Phase 3,Phase 2,Phase 1,Not Applicable

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Protective Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Calcium, Dietary

Phase 3,Phase 2

Antidotes

Phase 3,Phase 2,Phase 1,Not Applicable

Antibodies, Monoclonal

Phase 3,Phase 2,Phase 1

Antibodies

Phase 3,Phase 2,Phase 1

Immunoglobulins

Phase 3,Phase 2,Phase 1

Liver Extracts

Phase 3,Phase 2,Phase 1,Not Applicable

Pharmaceutical Solutions

Phase 3,Phase 2

Micronutrients

Phase 3,Phase 2,Phase 1,Not Applicable

Vitamin B9

Phase 3,Phase 2,Phase 1,Not Applicable

Vitamins

Phase 3,Phase 2,Phase 1,Not Applicable

Trace Elements

Phase 3,Phase 2,Phase 1,Not Applicable

Folate

Phase 3,Phase 2,Phase 1,Not Applicable

Vitamin B Complex

Phase 3,Phase 2,Phase 1,Not Applicable

Bone Density Conservation Agents

Phase 3,Phase 2

Immunoglobulin G

Phase 3,Phase 2

Endothelial Growth Factors

Phase 3,Phase 2

Mitogens

Phase 3,Phase 2,Phase 1

Tetrahydrofolates

Phase 3

Formyltetrahydrofolates

Phase 3

Mitomycins

Phase 2, Phase 3

s 1 (combination)

Phase 3

Paclitaxel

Approved, Vet_approved

Phase 2,Phase 1

33069-62-4

36314

Miconazole

Approved, Investigational, Vet_approved

Phase 2,Phase 1

22916-47-8

4189

Sirolimus

Approved, Investigational

Phase 2,Phase 1

53123-88-9

46835353 6436030 5284616

Everolimus

Approved

Phase 2,Phase 1

159351-69-6

6442177

Celecoxib

Approved, Investigational

Phase 2

169590-42-5

2662

Gefitinib

Approved, Investigational

Phase 2

184475-35-2

123631

Interventional clinical trials:

(show top 50) (show all 133)

#	Name	Status	NCT ID	Phase	Drugs
1	Intravenous Iron: Measuring Response in Anemic Surgical Patients	Completed	NCT02057471	Phase 4	Intravenous ferric carboxymaltose
2	IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia	Completed	NCT01701310	Phase 4	Ferric carboxymaltose;Ferrous Sulphate
3	A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)	Completed	NCT02788279	Phase 3	Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib
4	Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases	Completed	NCT00265356	Phase 3
5	A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer	Completed	NCT00623805	Phase 3	Bevacizumab;Capecitabine;Oxaliplatin
6	Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM	Recruiting	NCT03125161	Phase 3	HAI;chemotherapy ± target therapy
7	Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer	Recruiting	NCT02997228	Phase 3	Atezolizumab;Fluorouracil;Leucovorin Calcium;Oxaliplatin
8	5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab	Recruiting	NCT03300609	Phase 3	Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine
9	Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases	Recruiting	NCT02758951	Phase 2, Phase 3
10	Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）	Active, not recruiting	NCT02390947	Phase 3	Famitinib;Placebo
11	Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma	Not yet recruiting	NCT03708536	Phase 3	S-1;Bevacizumab;Capecitabine
12	TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases)	Not yet recruiting	NCT03783559	Phase 3	TACE;chemotherapy±target therapy
13	Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma	Unknown status	NCT01552967	Phase 2	Capecitabine
14	Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .	Unknown status	NCT02788006	Phase 2	Regorafenib 160 mg
15	Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.	Unknown status	NCT01067053	Phase 2	bevacizumab, capecitabine, oxaliplatin
16	Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma	Unknown status	NCT00075556	Phase 2	capecitabine
17	Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer	Unknown status	NCT00544011	Phase 2	capecitabine;fluorouracil;irinotecan hydrochloride
18	Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer	Unknown status	NCT00104689	Phase 2	capecitabine;oxaliplatin
19	Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer	Unknown status	NCT00027833	Phase 2	FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
20	Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma	Completed	NCT00034190	Phase 2	S-8184 Paclitaxel Injectable Emulsion
21	Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)	Completed	NCT01900717	Phase 2	LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
22	Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma	Completed	NCT00168155	Phase 2	perioperative chemotherapy
23	Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.	Completed	NCT02181465	Phase 2
24	Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma	Completed	NCT00574171	Phase 2	lapatinib;Capecitabine
25	Efficacy and Safety of Simtuzumab With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma	Completed	NCT01479465	Phase 2	Simtuzumab;FOLFIRI;Placebo to match simtuzumab
26	DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma	Completed	NCT00080834	Phase 2	DJ-927
27	Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy	Completed	NCT00419159	Phase 2	Everolimus (RAD001)
28	Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus	Completed	NCT00597506	Phase 2	Bevacizumab;Everolimus
29	Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma	Completed	NCT00165217	Phase 2	Capecitabine;Thalidomide
30	Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas	Completed	NCT01730586	Phase 2	Abraxane
31	Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib	Completed	NCT00582660	Phase 2	Celecoxib;Placebo
32	Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer	Completed	NCT00003220	Phase 2	bryostatin 1
33	Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer	Completed	NCT00025350	Phase 2	gefitinib
34	Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone	Completed	NCT00890305	Phase 2	CT-011;FOLFOX
35	Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver	Completed	NCT00149396	Phase 1, Phase 2	NV1020
36	1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer	Completed	NCT01417494	Phase 2	Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen);Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab
37	Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer	Completed	NCT00123851	Phase 2	Tarceva (OSI-774);Capecitabine;Oxaliplatin
38	Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy	Completed	NCT01225744	Phase 2	Cetuximab;Irinotecan;Oxaliplatin;UFT
39	Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed	Completed	NCT00259844	Phase 2
40	Azacitidine and CAPOX in Metastatic Colorectal Cancer	Completed	NCT01193517	Phase 1, Phase 2	Azacitidine;Capecitabine;Oxaliplatin;Azacitidine MTD
41	Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal ADenocarcinoma	Recruiting	NCT01844076	Phase 1, Phase 2	Phase I (Quinacrine);Capecitabine
42	Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma	Recruiting	NCT03559543	Phase 2
43	Chemotherapy and/or Metastasectomy in Treating Participants With Metastatic Colorectal Adenocarcinoma With Lung Metastases	Recruiting	NCT03599752	Phase 2	Chemotherapy
44	FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation	Recruiting	NCT03584711	Phase 2
45	Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases	Recruiting	NCT02185443	Phase 2
46	Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer	Recruiting	NCT03642067	Phase 2	Nivolumab;Relatlimab
47	Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver	Recruiting	NCT03069950	Phase 2	Floxuridine (FUDR);Irinotecan (CPT-11);FLUOROURACIL;PANITUMUMAB;DEXAMETHASONE;Leucovorin
48	Trial of Liver Resection Versus No Surgery in Patients With Liver and Unresectable Pulmonary Metastases From Colorectal Cancer (Liver Resection With Unresectable Lung Nodules From Colorectal Adenocarcinoma - LUNA)	Recruiting	NCT02738606	Phase 2	Chemotherapy
49	PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC	Recruiting	NCT03442569	Phase 2	Panitumumab;Nivolumab;Ipilimumab
50	Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer	Recruiting	NCT01053013	Phase 2

Search NIH Clinical Center for Large Intestine Adenocarcinoma

Sources

Genetic Tests for Large Intestine Adenocarcinoma

Sources

Anatomical Context for Large Intestine Adenocarcinoma

MalaCards organs/tissues related to Large Intestine Adenocarcinoma:

⁴¹

Lung, Kidney, Colon, Tongue, Ovary, Thymus, Appendix

Sources

Publications for Large Intestine Adenocarcinoma

Sources

Genes for Large Intestine Adenocarcinoma

Genes related to Large Intestine Adenocarcinoma (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	KRT20	Keratin 20	Protein Coding	15.55	DISEASES inferred ¹⁵
2	KRT7	Keratin 7	Protein Coding	14.02	DISEASES inferred ¹⁵
3	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	13.55	DISEASES inferred ¹⁵
4	CDH1	Cadherin 1	Protein Coding	13.24	DISEASES inferred ¹⁵
5	CTNNB1	Catenin Beta 1	Protein Coding	13.11	DISEASES inferred ¹⁵
6	MCM3	Minichromosome Maintenance Complex Component 3	Protein Coding	5.89	DISEASES inferred ¹⁵
7	PIP	Prolactin Induced Protein	Protein Coding	4.98	DISEASES inferred ¹⁵
8	EIF4EBP1	Eukaryotic Translation Initiation Factor 4E Binding Protein 1	Protein Coding	4.66	DISEASES inferred ¹⁵

Sources

Variations for Large Intestine Adenocarcinoma

Sources

Expression for Large Intestine Adenocarcinoma

Search GEO for disease gene expression data for Large Intestine Adenocarcinoma.

Sources

Pathways for Large Intestine Adenocarcinoma

Pathways related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 21)

#	Super pathways	Score	Top Affiliating Genes
1	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.45	CDH1 CTNNB1 EIF4EBP1 MTOR
2	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ¹	12.25	CDH1 CTNNB1 MTOR
3	Cytoskeletal Signaling ⁴	12.23	CDH1 KRT20 KRT7
4	Integrated Breast Cancer Pathway ¹	11.69	CDH1 CTNNB1 MTOR
5	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	11.6	CTNNB1 EIF4EBP1 MTOR
6	Development HGF signaling pathway ²² Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development Neurotrophin family signaling ²² MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ Neurotrophin signaling pathway ³⁷ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	11.55	CDH1 CTNNB1 EIF4EBP1 MTOR
7	Brain-Derived Neurotrophic Factor (BDNF) signaling pathway ¹	11.49	CTNNB1 EIF4EBP1 MTOR
8	Interferon type I signaling pathways ¹	11.34	EIF4EBP1 MTOR
9	Wnt Signaling Pathway Netpath ¹	11.32	CTNNB1 MTOR
10	Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway ¹	11.25	EIF4EBP1 MTOR
11	Arf6 trafficking events ¹	11.2	CDH1 CTNNB1
12	Cell adhesion_Cadherin-mediated cell adhesion ²²	11.15	CDH1 CTNNB1
13	Stabilization and expansion of the E-cadherin adherens junction ¹	11.14	CDH1 CTNNB1
14	BDNF-TrkB Signaling ¹	11.06	EIF4EBP1 MTOR
15	E-cadherin signaling in the nascent adherens junction ¹	11.03	CDH1 CTNNB1
16	Extracellular vesicle-mediated signaling in recipient cells ¹	10.97	CTNNB1 MTOR
17	PI3K-AKT-mTOR signaling pathway and therapeutic opportunities ¹	10.95	EIF4EBP1 MTOR
18	Follicle Stimulating Hormone (FSH) signaling pathway ¹	10.89	EIF4EBP1 MTOR
19	Nectin adhesion pathway ¹	10.83	CDH1 CTNNB1
20	4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression ¹	10.62	EIF4EBP1 MTOR
21	RHO GTPases activate IQGAPs ⁶⁶	10.07	CDH1 CTNNB1

Sources

GO Terms for Large Intestine Adenocarcinoma

Cellular components related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	catenin complex	GO:0016342	9.16	CDH1 CTNNB1
2	apical junction complex	GO:0043296	8.96	CDH1 CTNNB1
3	flotillin complex	GO:0016600	8.62	CDH1 CTNNB1

Biological processes related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of epithelial to mesenchymal transition	GO:0010718	9.4	CTNNB1 MTOR
2	adherens junction organization	GO:0034332	9.37	CDH1 CTNNB1
3	regulation of myelination	GO:0031641	9.32	CTNNB1 MTOR
4	TOR signaling	GO:0031929	9.26	EIF4EBP1 MTOR
5	regulation of osteoclast differentiation	GO:0045670	9.16	CTNNB1 MTOR
6	entry of bacterium into host cell	GO:0035635	8.96	CDH1 CTNNB1
7	cellular response to indole-3-methanol	GO:0071681	8.62	CDH1 CTNNB1

Sources

Sources for Large Intestine Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia